Health Care & Life Sciences » Pharmaceuticals | Dong-A ST Co. Ltd.

Dong-A ST Co. Ltd. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
500,967
578,640
567,940
560,535
555,027
567,434
Cost of Goods Sold (COGS) incl. D&A
237,561
270,840
276,365
286,652
277,883
276,988
Gross Income
263,407
307,800
291,575
273,883
277,144
290,446
SG&A Expense
219,847
253,855
233,766
254,877
248,505
246,141
EBIT
39,774
49,369
-
14,735
22,937
39,435
Unusual Expense
3,240
2,734
1,753
2,449
2,553
1,609
Non Operating Income/Expense
10,318
10,543
20,479
1,812
22,365
9,954
Interest Expense
11,755
14,164
15,481
11,952
8,579
6,851
Pretax Income
16,918
45,731
62,507
628
8,348
16,073
Income Tax
82,626
8,181
15,002
2,009
2,952
8,065
Consolidated Net Income
65,709
37,550
47,506
2,637
5,396
8,009
Net Income
65,715
37,412
47,506
2,637
5,396
8,009
Net Income After Extraordinaries
65,715
37,412
46,449
5,354
5,396
8,009
Net Income Available to Common
65,715
37,412
48,562
3,944
5,396
8,009
EPS (Basic)
8,997.00
4,966.00
6,192.00
1,267.75
639.00
949.09
Basic Shares Outstanding
7
8
8
8
8
8
EPS (Diluted)
8,997.12
4,673.49
6,191.90
1,267.75
639.39
949.09
Diluted Shares Outstanding
7
8
8
8
8
8
EBITDA
60,176
74,288
77,112
35,810
44,661
59,471
Other Operating Expense
3,785
4,576
3,946
4,272
5,702
4,869
Non-Operating Interest Income
2,457
2,716
1,893
2,106
2,212
4,556
Minority Interest Expense
7
137
-
-
-
-

About Dong-A ST Co.

View Profile
Address
64 Cheonhodae-ro
Seoul SL 02587
Korea, Republic Of
Employees -
Website http://www.donga-st.com
Updated 07/08/2019
Dong-A ST Co., Ltd. engages in the manufacture and sale of pharmaceutical products. Its products includes medicines for gastric mucous membrane protection, antihistanminic agetnts, ischemic improvements, antithrombotic, functional digestion, hyperlipemia cure, growth hormone, antipeptic ulcer cure, cerebral metabolic, high blood pressure, and others. The company was founded on March 4, 2013 and is headquartered in Seoul, South Korea.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.